VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-3.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.17% | 28.37% | 1.11% | -29.25% | -50.52% |
| Total Depreciation and Amortization | 0.00% | 50.00% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.25% | 185.06% | -32.75% | -14.87% | 29.95% |
| Change in Net Operating Assets | -62.94% | -215.01% | -16.18% | 421.83% | 133.78% |
| Cash from Operations | 5.74% | -27.36% | -5.75% | -0.33% | -6.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.43% | 54.27% | 366.48% | -125.36% | 632.92% |
| Cash from Investing | -76.43% | 55.68% | 364.05% | -125.36% | 632.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 60.92% | 34.09% | -6,500.00% | 0.00% | 60.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 60.92% | 34.09% | -6,500.00% | 0.00% | 60.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -174.39% | 129.64% | 127.05% | -226.58% | 191.18% |